Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 3115 of 3330
Next
>>
>
77851 to 77875 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.0000853	uM	5904.074	0.9677	0.9331	0.9654
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.000427	uM	5904.074	0.9803	0.9592	0.9654
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.00213	uM	5904.074	0.9267	0.8484	0.9654
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.0107	uM	5904.074	1.0094	1.0194	0.9654
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.0533	uM	5904.074	1.0315	1.0654	0.9654
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.267	uM	5904.074	0.8219	0.6324	0.9654
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	1.33	uM	5904.074	0.6238	0.2266	0.9654
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	6.67	uM	5904.074	0.5576	0.0921	0.9654
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	33.3	uM	5904.074	0.4035	-0.2190	0.9654
BT-474	HER2amp	Luminal	Triciribine	AKT	AKT	0.0000853	uM	5905.074	0.9845	0.9642	0.8648
BT-474	HER2amp	Luminal	Triciribine	AKT	AKT	0.000427	uM	5905.074	0.9821	0.9586	0.8648
BT-474	HER2amp	Luminal	Triciribine	AKT	AKT	0.00213	uM	5905.074	0.9282	0.8349	0.8648
BT-474	HER2amp	Luminal	Triciribine	AKT	AKT	0.0107	uM	5905.074	0.8965	0.7627	0.8648
BT-474	HER2amp	Luminal	Triciribine	AKT	AKT	0.0533	uM	5905.074	0.8356	0.6248	0.8648
BT-474	HER2amp	Luminal	Triciribine	AKT	AKT	0.267	uM	5905.074	0.7192	0.3662	0.8648
BT-474	HER2amp	Luminal	Triciribine	AKT	AKT	1.33	uM	5905.074	0.3684	-0.3698	0.8648
BT-474	HER2amp	Luminal	Triciribine	AKT	AKT	6.67	uM	5905.074	0.5048	-0.0927	0.8648
BT-474	HER2amp	Luminal	Triciribine	AKT	AKT	33.3	uM	5905.074	0.4199	-0.2667	0.8648
BT-474	HER2amp	Luminal	Triciribine	AKT	AKT	0.0000853	uM	5906.074	1.0186	1.0582	0.6442
BT-474	HER2amp	Luminal	Triciribine	AKT	AKT	0.000427	uM	5906.074	1.0117	1.0364	0.6442
BT-474	HER2amp	Luminal	Triciribine	AKT	AKT	0.00213	uM	5906.074	1.0583	1.1839	0.6442
BT-474	HER2amp	Luminal	Triciribine	AKT	AKT	0.0107	uM	5906.074	0.7444	0.2648	0.6442
BT-474	HER2amp	Luminal	Triciribine	AKT	AKT	0.0533	uM	5906.074	0.7377	0.2472	0.6442
BT-474	HER2amp	Luminal	Triciribine	AKT	AKT	0.267	uM	5906.074	0.7139	0.1853	0.6442
BT-474	HER2amp	Luminal	Triciribine	AKT	AKT	1.33	uM	5906.074	0.6440	0.0102	0.6442

|<
<<
Previous
Page 3115 of 3330
Next
>>
>
77851 to 77875 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)